NCT02427750View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Human Influenza

Interventions

BIOLOGICAL

Aggripal®

TIV

Trial Locations (1)

40420000

100, Salvador

Sponsors

Lead Sponsor

Collaborators (1)

Novartis Vaccines

All Listed Sponsors

collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT02427750 - A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects. | Biotech Hunter | Biotech Hunter